Day: September 29, 2021

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.

SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and benign prostatic hyperplasia (BPH) (the “Product”), Aquestive Therapeutics, Inc. (NASDAQ:AQST) (“Aquestive”), has entered into a definitive license and supply agreement (the “Agreement”) with an undisclosed leading men’s health company. “Securing this commercial partnership is a significant milestone in our innovative collaboration with Aquestive, and represents another major step toward achieving our mutual goal of making Tadalafil oral films available to men suffering from ED and BPH,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. About Aquestive Therapeutics Aquestive...

Continue reading

<div>Targa Resources Corp. to Participate in Wolfe Research Utilities, Midstream & Clean Energy Conference</div>

Targa Resources Corp. to Participate in Wolfe Research Utilities, Midstream & Clean Energy Conference

HOUSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings via video conference at the Wolfe Research Utilities, Midstream & Clean Energy Conference on Thursday, September 30, 2021. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary...

Continue reading

Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows: Date:   Thursday, September 30, 2021   Time:    10:10AM ET Webcast Link:   https://www.benzinga.com/events/small-cap/healthcare/ The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.pasithea.com, under the Investors section. About Pasithea Therapeutics Corp. Pasithea Therapeutics Corp. is a biotechnology company focused on the research and...

Continue reading

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing of its previously announced registered direct offering for the purchase and sale of 77,777,779 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 77,777,779 shares of common stock, at an effective purchase price of $0.09 per share (or common stock equivalent in lieu thereof) and associated warrant. H.C. Wainwright & Co. acted as the exclusive placement agent for the registered direct offering. The warrants have an exercise price equal to $0.09 per share, are exercisable...

Continue reading

Alamos Gold Provides Notice of Third Quarter 2021 Results and Conference Call

Alamos Gold Provides Notice of Third Quarter 2021 Results and Conference Call

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its third quarter 2021 financial results after market close on Wednesday, October 27, 2021. Senior management will host a conference call on Thursday, October 28, 2021 at 11:00 am ET to discuss the results. Participants may join the conference call via webcast or through the following dial-in numbers: Toronto and International: (416) 406-0743 Toll free (Canada and the United States):  (800) 898-3989 Participant passcode:   8987852# Webcast: www.alamosgold.com  A playback will be available until November 28, 2021 by dialling (905) 694-9451 or (800) 408-3053 within Canada and the United States. The pass code is 5112333#. The webcast will be archived at www.alamosgold.com. About Alamos Alamos is a...

Continue reading

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum

REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018. “We will greatly miss Sam and his tremendous support for Coherus. Long before joining the Coherus board, he lived a mission of providing greater access to life-changing medicines,” said Denny Lanfear, CEO of Coherus. “We were privileged to benefit from his guidance and counsel during his time on our Board, and I will forever be grateful for his service. The entire Coherus team offers our condolences to the Nussbaum family at this time.” From 2000 to 2016, Dr. Nussbaum served...

Continue reading

Troika Media Reports Fourth Quarter and Fiscal 2021 Results and Forecasts Fiscal 2022 First Quarter Net Sales to Increase by Approximately 60% Versus the Prior-Year Period

Troika Media Reports Fourth Quarter and Fiscal 2021 Results and Forecasts Fiscal 2022 First Quarter Net Sales to Increase by Approximately 60% Versus the Prior-Year Period

Highlights of fiscal year 2021 Strengthened balance sheet with initial public offering (“IPO”) raising gross proceeds of $24.0 million Completed acquisition of Redeeem, now Troika IO, and launched new division, Troika Labs Continued focus on significant growth strategy post-COVID coupled with synergistic acquisitions Operating cost reduction to effectively manage business environment while selectively adding new strategic growth engines Significant highlights after the period Key new business wins including Wilson Sporting Goods, F45 Fitness, PointsBet, Pac-12 and VSPN Accelerating expansion in fast growing gaming and Esports market Demand for client services recovering in Q1 2022 with pipeline growing New client growth returning to pre-pandemic levels Strong net revenue recovery expected to continue in fiscal 2022 With tone of business...

Continue reading

Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

MannKind Corporation facility in Connecticut Exterior of MannKind Corporation’s facility in Danbury, Conn. WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing. “We are pleased to enter into this sale-leaseback transaction and unlock value tied up in our manufacturing facility that translates directly into non-dilutive capital to support our company’s growth and development strategy,” said Michael Castagna, PharmD,...

Continue reading

Almadex Closes Sale of 2.0% NSR on Elk Property

Almadex Closes Sale of 2.0% NSR on Elk Property

VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. and its 100% owned subsidiary Almadex Royalties Limited, (collectively “Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce the completion of the previously announced sale of its 2% net smelter return royalty on the Elk Property to Star Royalties Ltd. (“Star Royalties”) (TSXV: STRR, OTCQX: STRFF), as further described in the Company’s press release of September 28, 2021. Almadex currently has approximately CAD$16.5 million in cash and holds approximately 2.3% of the issued and outstanding shares of Star Royalties, not including the share purchase warrants, in addition to a mineral asset portfolio consisting of numerous exploration projects and NSR royalties in Canada, the U.S., and Mexico. The Company intends...

Continue reading

CTO Realty Growth Announces Third Quarter 2021 Earnings Release and Conference Call Information

CTO Realty Growth Announces Third Quarter 2021 Earnings Release and Conference Call Information

DAYTONA BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter 2021 after the market closes on Thursday, October 28, 2021. A conference call to discuss its financial and operating results is scheduled for Friday, October 29, 2021 at 9:00 AM ET (the “Earnings Call”). Shareholders and interested parties may access the Earnings Call via teleconference or webcast: Teleconference:  USA (Toll Free) 1-844-200-6205   International 1-929-526-1599       To access the conference call, enter 094458 when prompted.       Webcast: https://www.incommglobalevents.com/registration/q4inc/8800/cto-q3-2021-earnings-call/ To participate via teleconference, please dial-in approximately 10 minutes prior to the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.